Recombinant Human Erythropoietin Alfa is a glycoprotein hormone produced using recombinant DNA technology, identical in amino acid sequence to endogenous erythropoietin. It stimulates erythropoiesis by binding to the erythropoietin receptor on erythroid progenitor cells in the bone marrow. The 4000IU/ml concentration is a standard strength for subcutaneous or intravenous administration, primarily used for anemia correction in chronic kidney disease and chemotherapy-induced anemia.
Adult: CKD: Initial SC/IV dose 50-100 IU/kg 3 times weekly. Adjust based on Hb response. Target Hb: 10-12 g/dL. Chemotherapy-induced anemia: 150 IU/kg SC 3 times weekly or 40,000 IU SC weekly. Adjust to lowest dose to avoid transfusion.
Note: For subcutaneous use: Rotate injection sites (abdomen, thigh, upper arm). Do not shake vial. Administer as a slow injection. For intravenous use in dialysis patients: Administer via venous line at end of dialysis session. Single-use vials; discard unused portion.
Epoetin alfa binds to the erythropoietin receptor (EpoR) on the surface of committed erythroid progenitor cells (CFU-E and some BFU-E) in the bone marrow. This binding activates the JAK2/STAT5 intracellular signaling pathway, promoting cell survival, proliferation, and terminal differentiation into mature red blood cells. It also stimulates the release of reticulocytes from the bone marrow into the circulation.
Pregnancy: Category C: Animal studies show risk. Use only if potential benefit justifies potential fetal risk. No controlled studies in pregnant women. May exacerbate pregnancy-induced hypertension.
Driving: Dizziness and headache may occur; caution advised when driving or operating machinery until response is known.
| Heparin | Increased risk of vascular access thrombosis in dialysis patients. | Moderate |
| Cyclosporine, Tacrolimus | May potentiate hypertensive effects; monitor BP closely. | Moderate |
| ACE Inhibitors (e.g., Enalapril) | May blunt erythropoietic response; may require higher EPO dose. | Moderate |
| Androgens (e.g., Danazol) | Additive effect on erythropoiesis; may increase thrombotic risk. | Moderate |
Same composition (Recombinant Human Erythropoietin Alfa (4000IU/ml)), different brands: